The eukaryotic translation initiation factor eIF4E is elevated in about 30% of cancers. eIF4E promotes proliferation and survival by the coordinated upregulation of the expression of genes involved in these pathways. eIF4E functions in both the nucleus and cytoplasm. In the cytoplasm, it binds the 7-methyl guanosine (m7G) cap found on the 5'end of mRNAs thereby allowing translation initiation. Importantly, up to 68% of eIF4E is found in the nucleus, where it promotes mRNA export of a subset of transcripts coding for proteins involved in survival and proliferation. This mRNA export activity contributes substantially to its oncogenicity. eIF4E must bind the m7G cap to act in translation, export and transformation. We found that inhibition of eIF4E function by introduction of a physical mimic of the m7G cap, ribavirin, leads to inhibition of eIF4E's survival and proliferative activities, and is associated with clinical benefit in leukemia patients. Although eIF4E's role in translation is well understood, its molecular role in mRNA export is not. Our studies revealed that eIF4E dependent mRNA export is distinct from bulk mRNA export, being CRM1 dependent. We will examine the extent to which eIF4E dependent mRNA export uses the CRM1 export machinery. Further, we identified a 50-nucleotide element in the untranslated region of target mRNAs referred to as an eIF4E sensitivity element (4E-SE). The 4E-SE imparts sensitivity to eIF4E (allowing preferential export). In subsequent studies we identified a factor, the leucine-rich pentatricopeptide repeat protein LRP, which directly binds the 4E-SE element. We will examine the role LRP plays in this export process. Finally, we will examine the impact on eIF4E activity of a novel partner, the inhibitor of invasion protein IIp45. IIp45 appears to impair eIF4E function in a new manner. We propose three specific aims to investigate these possibilities: 1. Determine the molecular mechanism of eIF4E dependent mRNA export, 2. Define the role that LRP plays in this pathway and 3. Examine novel modes of control of eIF4E by the IIp45 protein. We believe that elucidation of the molecular underpinnings of eIF4E dependent mRNA export will yield new insights into the mechanics of eIF4E-mediated transformation. Further, these findings could provide the basis for novel therapeutic strategies for cancers characterized by dysregulated eIF4E.

Public Health Relevance

The eukaryotic translation initiation factor eIF4E is dysregulated in many human cancers including cancers of the breast, head &neck, colon, prostate and blood. Our project is designed to understand the mechanisms and therapeutic implications of this dysregulation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA080728-13
Application #
8215246
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Mufson, R Allan
Project Start
1999-04-01
Project End
2013-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
13
Fiscal Year
2012
Total Cost
$195,671
Indirect Cost
$14,495
Name
University of Montreal
Department
Type
DUNS #
207622838
City
Montreal
State
PQ
Country
Canada
Zip Code
H3 3-J7
Borden, Katherine L B (2014) When will resistance be futile? Cancer Res 74:7175-80
Capulli, A K; Tian, K; Mehandru, N et al. (2014) Approaching the in vitro clinical trial: engineering organs on chips. Lab Chip 14:3181-6
Nesmith, Alexander Peyton; Agarwal, Ashutosh; McCain, Megan Laura et al. (2014) Human airway musculature on a chip: an in vitro model of allergic asthmatic bronchoconstriction and bronchodilation. Lab Chip 14:3925-36
Zahreddine, Hiba Ahmad; Culjkovic-Kraljacic, Biljana; Assouline, Sarit et al. (2014) The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature 511:90-3
Volpon, Laurent; Osborne, Michael J; Culjkovic-Kraljacic, Biljana et al. (2013) eIF4E3, a new actor in mRNA metabolism and tumor suppression. Cell Cycle 12:1159-60
Clozel, Thomas; Yang, ShaoNing; Elstrom, Rebecca L et al. (2013) Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov 3:1002-19
Culjkovic-Kraljacic, Biljana; Borden, Katherine L B (2013) Aiding and abetting cancer: mRNA export and the nuclear pore. Trends Cell Biol 23:328-35
Zahreddine, Hiba; Borden, Katherine L B (2013) Mechanisms and insights into drug resistance in cancer. Front Pharmacol 4:28
Borden, Katherine L B; Culjkovic-Kraljacic, Biljana (2010) Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond? Leuk Lymphoma 51:1805-15
Borden, Katherine L B (2008) Pondering the puzzle of PML (promyelocytic leukemia) nuclear bodies: can we fit the pieces together using an RNA regulon? Biochim Biophys Acta 1783:2145-54

Showing the most recent 10 out of 32 publications